.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Mallinckrodt
Cerilliant
Farmers Insurance
Dow
Argus Health
Cantor Fitzgerald
Harvard Business School
Teva
Federal Trade Commission

Generated: July 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075990

« Back to Dashboard
NDA 075990 describes LORATADINE, which is a drug marketed by Perrigo, Taro, Teva, Sandoz, Perrigo Pharma Intl, Marksans Pharma, Wockhardt, Silarx, Pfizer, Ranbaxy Labs Ltd, Sun Pharm Inds Ltd, Mylan, Apotex Inc, Taro Pharm, and Actavis Labs Fl Inc, and is included in twenty-seven NDAs. It is available from one hundred and twenty suppliers. Additional details are available on the LORATADINE profile page.

The generic ingredient in LORATADINE is loratadine; pseudoephedrine sulfate. There are thirty-nine drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the loratadine; pseudoephedrine sulfate profile page.

Summary for NDA: 075990

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 075990

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LORATADINE
loratadine
TABLET, ORALLY DISINTEGRATING;ORAL 075990 ANDA Target Corporation 11673-311 11673-311-65 3 BLISTER PACK in 1 CARTON (11673-311-65) > 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
LORATADINE
loratadine
TABLET, ORALLY DISINTEGRATING;ORAL 075990 ANDA Amerisource Bergen 24385-518 24385-518-52 1 BLISTER PACK in 1 CARTON (24385-518-52) > 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:OTCDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength10MG
Approval Date:Nov 3, 2003TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Argus Health
Baxter
Cipla
US Department of Justice
Moodys
Daiichi Sankyo
Harvard Business School
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot